<code id='CE5B81FE83'></code><style id='CE5B81FE83'></style>
      • <acronym id='CE5B81FE83'></acronym>
      <center id='CE5B81FE83'><center id='CE5B81FE83'><tfoot id='CE5B81FE83'></tfoot></center><abbr id='CE5B81FE83'><dir id='CE5B81FE83'><tfoot id='CE5B81FE83'></tfoot><noframes id='CE5B81FE83'>
      • <optgroup id='CE5B81FE83'><strike id='CE5B81FE83'><sup id='CE5B81FE83'></sup></strike><code id='CE5B81FE83'></code></optgroup>
        5. <b id='CE5B81FE83'><label id='CE5B81FE83'><select id='CE5B81FE83'><dt id='CE5B81FE83'><span id='CE5B81FE83'></span></dt></select></label></b><u id='CE5B81FE83'></u>
          <i id='CE5B81FE83'><strike id='CE5B81FE83'><tt id='CE5B81FE83'><pre id='CE5B81FE83'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-27 12:28:47 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      Page View：287
                                  
                                    
          
                                   
          Editor’s note: A recording of the event is embedded below.
          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
          advertisement
          Featured Speakers
          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry
                                
                            
          Next article：  
                                      
                                          Sports medicine is finally prioritizing gender equality
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles